NASDAQ
Design Therapeutics, Inc. (DSGN)
♥ 615 Thanks from members
Design Therapeutics (DSGN) maintains a solid liquidity position with over $207 million in cash and a runway into 2029, though near-term market momentum faces headwinds from pushed-out clinical data timelines and small trial cohorts.